UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 7, 2005
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
|
|
|
|
|
|
|
128 Sidney Street, Cambridge, MA 02139 |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (617) 995-2500 |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 – OTHER EVENTS
On February 9, 2005, ImmunoGen, Inc. issued a press release to announce that Boehringer Ingelheim – one of ImmunoGen’s collaborative partners – has decided to discontinue its development of bivatuzumab mertansine. Bivatuzumab mertansine consists of the Boehringer Ingelheim anti-CD44v6 antibody, bivatuzumab, and ImmunoGen’s DM1 cytotoxic agent, mertansine. Boehringer Ingelheim is retaining its right to use ImmunoGen’s DM1 Tumor-Activated Prodrug (TAP) technology for a different antigen target. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
The information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated February 9, 2005 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
|
(Registrant) |
|
|
|
|
|
|
Date: February 9, 2005 |
/s/ Karleen M. Oberton |
|
|
|
|
|
|
|
Karleen M. Oberton |
|
|
|
Senior Corporate Controller |
|
|
|
(Principal Accounting and Financial Officer) |
|
3